Talquetamab, a GPRC5DXCD3 Bispecific Antibody, for Treatment of Relapsed/Refractory Multiple Myeloma in Patients With Prior Exposure to BCMA Targeted Therapies - a "Real World" Study

被引：0
|
作者：
Shkury, Eden [1 ]
Hellou, Tamer [2 ]
Nevo, Lee [2 ]
Avigdor, Abraham [2 ]
Magen, Hila [2 ]
机构：
[1] Sheba Tel HaShomer Med Ctr, Tel Hashomer, Israel
[2] Tel Aviv Univ, Chaim Sheba Med Ctr, Fac Med & Hlth Sci, Tel Aviv, Israel
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2024年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-081
引用
收藏
页码：S88 / S89
页数：2
相关论文
共 50 条
  • [21] The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
    Hammons, Lindsay
    Szabo, Aniko
    Janardan, Abhishek
    Bhatlapenumarthi, Vineel
    Annyapu, Evanka
    Dhakal, Binod
    Al Hadidi, Samer
    Radhakrishnan, Sabarinath Venniyil
    Narra, Ravi
    Bhutani, Divaya
    Thanendrarajan, Sharmilan
    Janz, Siegfried
    Zangari, Maurizio
    Lentzsch, Suzanne
    van Rhee, Frits
    Crescencio, Juan Carlos Rico
    D'Souza, Anita
    Chakraborty, Rajshekhar
    Mohan, Meera
    Schinke, Carolina
    HAEMATOLOGICA, 2024, 109 (03) : 906 - 914
  • [22] Characterization and management of oral and dermatological toxicities in patients receiving the CD3 X GPRC5D bispecific antibody talquetamab for the treatment of relapsed/refractory multiple myeloma
    Aronson, Elizabeth
    Purcell, Kiah
    Aponte, Annel
    Louw, Karen
    Catamero, Donna
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S195 - S195
  • [23] BCMA x CD3 bispecific antibody treatment with teclistamab in relapsed and/or refractory multiple myeloma: a real-world monocentric analysis
    Schaefers, C.
    Thiele, B.
    Alsdorf, W.
    Kosch, R.
    Leypoldt, L.
    Bokemeyer, C.
    Weisel, K.
    Kamili, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 312 - 312
  • [24] Co-Expression of GPRC5D, FcRH5 and BCMA Suggests That Targeting More Than One Cell Surface Marker May be a Viable Strategy in Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from the Phase I Study of Forimtamig, a GPRC5DxCD3 Bispecific Antibody
    Dekhtiarenko, Iryna
    Lelios, Iva
    Jacob, Wolfgang
    Schneider, Meike
    Weisser, Martin
    Carlo-Stella, Carmelo
    Manier, Salomon
    Harrison, Simon J.
    Popat, Rakesh
    Riley, Anna Caroline Hasselbalch
    Broeke, Ann-Marie E.
    BLOOD, 2023, 142
  • [25] Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study
    Dekhtiarenko, Iryna
    Lelios, Iva
    Attig, Jan
    Sleiman, Nassim
    Lazzaro, Domenico
    Schindler, Emilie
    Eckmann, Jan
    Umana, Pablo
    Jacob, Wolfgang
    Schneider, Meike
    Carlo-Stella, Carmelo
    Mazza, Rita
    Manier, Salomon
    Facon, Thierry
    Yoon, Sung-Soo
    Koh, Youngil
    Harrison, Simon J.
    Er, Jeremy
    Pinto, Antonio
    Volzone, Francesco
    Perrone, Giulia
    Corradini, Paolo
    Cazaubiel, Titouan
    Hulin, Cyrille
    Touzeau, Cyrille
    Moreau, Philippe
    Ocio, Enrique M.
    Gaisan, Carmen Maria Montes
    Popat, Rakesh
    Leong, Sarah
    Offner, Fritz
    Otero, Paula Rodriguez
    Alfonso-Pierola, Ana
    Hutchings, Martin
    Riley, Caroline Hasselbalch
    Broske, Ann-Marie E.
    BLOOD, 2022, 140 : 10137 - 10139
  • [26] Real World Experience of Standard of Care Talquetamab in Patients with Relapsed and Refractory Multiple Myeloma
    Grajales-cruz, Ariel
    Graeter, Allison
    Hansen, Doris
    Puglianini, Omar Castaneda
    Vazquez-Martinez, Mariola
    Blue, Brandon
    Liu, Hien
    Ochoa-Bayona, Jose
    Freeman, Ciara
    Locke, Frederick
    Nishihori, Taiga
    Shain, Kenneth
    Baz, Rachid
    Alsina, Melissa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S56 - S56
  • [27] Effect of talquetamab on responses in patients with relapsed and refractory multiple myeloma with prior exposure to T-cell directed therapies.
    Graeter, Allison
    Alexis, Omar
    Puglianini, Castaneda
    Hansen, Doris K.
    Vazquez-Martinez, Mariola A.
    Blue, Brandon Jamaal
    Khadka, Sushmita
    Liu, Hien
    Ochoa-Bayona, Jose L.
    Freeman, Ciara L.
    Locke, Frederick L.
    Nishihori, Taiga
    Shain, Kenneth H.
    Baz, Rachid C.
    Alsina, Melissa
    Grajales-Cruz, Ariel Felipe
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Firestone, Ross
    Shekarkhand, Tala
    Patel, Dhwani
    Tan, Carlyn Rose Co
    Hultcrantz, Malin
    Lesokhin, Alexander M.
    Mailankody, Sham
    Hassoun, Hani
    Shah, Urvi A.
    Korde, Neha
    Maclachlan, Kylee
    Landau, Heather Jolie
    Scordo, Michael
    Chung, David J.
    Shah, Gunjan L.
    Lahoud, Oscar Boutros
    Giralt, Sergio
    Usmani, Saad Zafar
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Characterization and Management of Oral and Dermatological Toxicities in Patients Receiving the CD3 X GPRC5D Bispecific Antibody Talquetamab (JNJ-64407564) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
    Mancia, Stefania Stefania
    Farrell, Annamaria
    Louw, Karen
    Florendo, Erika
    Aronson, Elizabeth
    Purcell, Kiah
    Catamero, Donna D.
    Escalon, Juliet
    Thomas, Joanne
    Aponte, Annel
    Lamb, Angela
    Kirke, Diana
    Lucas, Aimee
    Jagannath, Sundar
    Cho, Hearn Jay
    Parekh, Samir
    Richter, Joshua
    Sanchez, Larysa
    Chari, Ajai
    BLOOD, 2021, 138
  • [30] A German Multicenter Real-World Analysis of Talquetamab in 102 Patients With Relapsed/ Refractory Multiple Myeloma
    Frenking, Jan
    Riedhammer, Christine
    Besemer, Britta
    Braune, Jan
    Brioli, Annamaria
    Brunner, Franziska
    Dampmann, Maria
    Gezer, Deniz
    Goldman-Mazur, Sarah
    Haenel, Mathias
    Hanoun, Christine
    Hoegner, Marion
    Kolditz, Katja
    Kos, Igor
    Kull, Miriam
    Leitner, Theo
    Merz, Maximilan
    von Metzler, Ivana
    Michel, Christian S.
    Teipel, Raphael
    Theurich, Sebastian
    Waesch, Ralph
    Zukovs, Romans
    Rasche, Leo
    Raab, Marc-Steffen
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S52 - S53
12345